AVCTAIM
Avacta Group
Joining is free.
Everyone here is a real person.
Looking for the Avacta Group share chat? This is where verified investors discuss Avacta Group, and where they build a collective voice the company has a reason to answer.
Which milestone funds the next one?
Clinical pipelines and balance sheets tend to get read separately, and with Avacta they are really the same question. Progress at a trial milestone changes the terms on which the next round of funding happens, and the gap between those two events is where dilution lives. I have no view worth having on the science. But for those who do: which readout actually changes the funding position?
Members’ discussion of Avacta Group is not published to the open web. It is available to verified members, and joining is free.
Why verified
Everyone here is a real person.
That leads to better conversations. Most share chat has a bot problem and a ramping problem. This community does not: every account is one verified person, and disagreeing with the crowd is welcome here.
Joining is free. Nicknames welcome.
There’s a two-minute identity check with a photo ID, run by Veriff, a verification partner of the kind banks use. We never see or hold your documents, only the result. Your identity is held privately and never shown on the board.
Key questions
How much progress is being made in advancing the clinical pipeline, and what would success or failure at key trial milestones mean for the company's prospects? Is the balance sheet strong enough to fund operations through to the next major value-creating event without excessive shareholder dilution?
Nothing on this page is investment advice or a recommendation to buy or sell any security. It is a place to discuss the companies you own with other verified owners.